Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality

OBJECTIVE: Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in patients with type 2 diabetes, with high-attendant cardiovascular risk, was associated with altered mortality in a retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Simon G, Hutchings, David C, Woodward, Mark, Rahimi, Kazem, Rutter, Martin K, Kirby, Mike, Hackett, Geoff, Trafford, Andrew W, Heald, Adrian H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Cardiac Risk Factors and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099221/
https://www.ncbi.nlm.nih.gov/pubmed/27465053
http://dx.doi.org/10.1136/heartjnl-2015-309223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099221/
https://www.ncbi.nlm.nih.gov/pubmed/27465053
http://dx.doi.org/10.1136/heartjnl-2015-309223

Ejemplares similares